Associated Papers
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Deng F et al.
Cancers, 2026
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.
Ghosh P et al.
Biochemical Society Transactions, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Lee JB et al.
Nature Reviews. Clinical Oncology, 2025
A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers.
Harada G et al.
Jto Clinical and Research Reports, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Nakazawa S et al.
Cancer Discovery, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.
Sattler M et al.
Cell Reports. Medicine, 2025
From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.
Bogdanska W et al.
Cancer, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Guérin C et al.
Biorxiv : the Preprint Server for Biology, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Elife, 2025
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
Lin H et al.
Communications Biology, 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.
Hu Y et al.
Lung Cancer (auckland, N.z.), 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X et al.
Journal of Cancer Research and Clinical Oncology, 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL et al.
The Lancet. Oncology, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X et al.
Clinical Chemistry, 2024
CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T et al.
Jto Clinical and Research Reports, 2024
Joint DNA-RNA-based NGS for diagnosis and treatment of a rare CD47-MET fusion lung adenocarcinoma which was immunoresistant and savoltinib-sensitive: a case report.
Wang R et al.
Frontiers in Immunology, 2024
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
Zhu J et al.
Lung Cancer (auckland, N.z.), 2024
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala EEJ et al.
Current Research in Pharmacology and Drug Discovery, 2024
Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Schmalz L et al.
Lung Cancer (amsterdam, Netherlands), 2023
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Jóri B et al.
Current Oncology (toronto, Ont.), 2023
A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L et al.
Anti-cancer Drugs, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J et al.
Molecular Cancer Therapeutics, 2023
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C et al.
Cancers, 2023
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
Kang J et al.
Lung Cancer (amsterdam, Netherlands), 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022